Bank of New York Mellon Corp Sells 296,060 Shares of GE HealthCare Technologies Inc. $GEHC

Bank of New York Mellon Corp decreased its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 9.3% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 2,898,345 shares of the company’s stock after selling 296,060 shares during the quarter. Bank of New York Mellon Corp’s holdings in GE HealthCare Technologies were worth $237,722,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Laurel Wealth Advisors LLC bought a new position in shares of GE HealthCare Technologies during the 4th quarter worth $26,000. Optima Capital LLC bought a new position in shares of GE HealthCare Technologies during the 4th quarter worth $27,000. Godfrey Financial Associates Inc. bought a new position in shares of GE HealthCare Technologies during the 4th quarter worth $27,000. Montag A & Associates Inc. grew its position in shares of GE HealthCare Technologies by 105.4% during the 4th quarter. Montag A & Associates Inc. now owns 341 shares of the company’s stock worth $28,000 after buying an additional 175 shares in the last quarter. Finally, Maseco LLP bought a new position in shares of GE HealthCare Technologies during the 4th quarter worth $29,000. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Trading Up 1.3%

Shares of NASDAQ GEHC opened at $64.67 on Friday. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.22 and a quick ratio of 0.95. The stock has a market capitalization of $29.42 billion, a P/E ratio of 15.47, a price-to-earnings-growth ratio of 1.44 and a beta of 0.74. GE HealthCare Technologies Inc. has a 1-year low of $58.75 and a 1-year high of $89.77. The business has a fifty day moving average price of $66.89 and a 200 day moving average price of $75.49.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing analysts’ consensus estimates of $1.07 by ($0.08). GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The business had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.04 billion. During the same quarter last year, the business posted $1.01 earnings per share. The company’s quarterly revenue was up 7.4% compared to the same quarter last year. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Equities research analysts expect that GE HealthCare Technologies Inc. will post 4.89 EPS for the current fiscal year.

Insider Buying and Selling

In other GE HealthCare Technologies news, Director Watkin Phoebe L. Yang purchased 1,000 shares of the firm’s stock in a transaction on Friday, May 8th. The stock was bought at an average cost of $63.01 per share, for a total transaction of $63,010.00. Following the completion of the purchase, the director owned 13,702 shares in the company, valued at $863,363.02. This represents a 7.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Rodney F. Hochman purchased 1,618 shares of the firm’s stock in a transaction on Tuesday, May 12th. The stock was acquired at an average price of $62.03 per share, with a total value of $100,364.54. Following the completion of the purchase, the director owned 1,618 shares of the company’s stock, valued at $100,364.54. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 21,847 shares of company stock valued at $1,361,355 in the last 90 days. 0.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the company. Citigroup decreased their price objective on GE HealthCare Technologies from $80.00 to $65.00 and set a “neutral” rating for the company in a research note on Thursday, April 30th. Jefferies Financial Group decreased their price objective on GE HealthCare Technologies from $105.00 to $90.00 in a research note on Thursday, April 30th. Wall Street Zen cut GE HealthCare Technologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 21st. Barclays decreased their price objective on GE HealthCare Technologies from $87.00 to $78.00 and set an “equal weight” rating for the company in a research note on Thursday, April 30th. Finally, Rothschild & Co Redburn decreased their price objective on GE HealthCare Technologies from $110.00 to $98.00 in a research note on Thursday, April 30th. Nine equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, GE HealthCare Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.21.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies (NASDAQ: GEHC) is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.